Evidence map›Paper›PMID 36386626›Full record

ArticleFrontiers in microbiology2022

Development of a rapid, simple, and sensitive point-of-care technology platform utilizing ternary NanoLuc.

Emily A Torio, Valerie T Ressler, Virginia A Kincaid, Robin Hurst, Mary P Hall, Lance P Encell, Kristopher Zimmerman, Stuart K Forsyth, William M Rehrauer, Molly A Accola and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Emily A TorioPromega Corporation, Madison, WI, United States.
Valerie T ResslerPromega Corporation, Madison, WI, United States.
Virginia A KincaidPromega Corporation, Madison, WI, United States.
Robin HurstPromega Corporation, Madison, WI, United States.
Mary P HallPromega Corporation, Madison, WI, United States.
Lance P EncellPromega Corporation, Madison, WI, United States.
Kristopher ZimmermanPromega Corporation, Madison, WI, United States.
Stuart K ForsythPromega Corporation, Madison, WI, United States.
William M RehrauerDepartment of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.
Molly A AccolaUniversity of Wisconsin Hospital and Clinics, Clinical Laboratories, Madison, WI, United States.
Chia-Chang HsuPromega Corporation, Madison, WI, United States.
Thomas MachleidtPromega Corporation, Madison, WI, United States.
Melanie L DartPromega Corporation, Madison, WI, United States.
Promega (United States) · USUW Health University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Point-of-care tests are highly valuable in providing fast results for medical decisions for greater flexibility in patient care. Many diagnostic tests, such as ELISAs, that are commonly used within clinical laboratory settings require trained technicians, laborious workflows, and complex instrumentation hindering their translation into point-of-care applications. Herein, we demonstrate the use of a homogeneous, bioluminescent-based, split reporter platform that enables a simple, sensitive, and rapid method for analyte detection in clinical samples. We developed this point-of-care application using an optimized ternary, split-NanoLuc luciferase reporter system that consists of two small reporter peptides added as appendages to analyte-specific affinity reagents. A bright, stable bioluminescent signal is generated as the affinity reagents bind to the analyte, allowing for proximity-induced complementation between the two reporter peptides and the polypeptide protein, in addition to the furimazine substrate. Through lyophilization of the stabilized reporter system with the formulated substrate, we demonstrate a shelf-stable, all-in-one, add-and-read analyte-detection system for use in complex sample matrices at the point-of-care. We highlight the modularity of this platform using two distinct SARS-CoV-2 model systems: SARS-CoV-2 N-antigen detection for active infections and anti-SARS-CoV-2 antibodies for immunity status detection using chemically conjugated or genetically fused affinity reagents, respectively. This technology provides a simple and standardized method to develop rapid, robust, and sensitive analyte-detection assays with flexible assay formatting making this an ideal platform for research, clinical laboratory, as well as point-of-care applications utilizing a simple handheld luminometer.

Indexed as

bioluminescenceNanoLuc complementationpoint-of-carerapid testingSARS-CoV-2 antigen

Identifiers

PMID36386626
PMCPMC9643700
OpenAlexW4307553158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.